Laminin, gamma 2 (LAMC2): A Promising New Putative Pancreatic Cancer Biomarker Identified by Proteomic Analysis of Pancreatic Adenocarcinoma Tissues
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In pancreatic cancer, the incidence and mortality curves coincide. One major reason for this high mortality rate in pancreatic ductal adenocarcinoma (PDAC) patients is the dearth of effective diagnostic, prognostic, and disease-monitoring biomarkers. Unfortunately, existing tumor markers, as well as current imaging modalities, are not sufficiently sensitive and/or specific for early-stage diagnosis. There is, therefore, an urgent need for improved serum markers of the disease. Herein, we performed Orbitrap® mass spectrometry proteomic analysis of four PDAC tissues and their adjacent benign tissues and identified a total of 2190 nonredundant proteins. Sixteen promising candidates were selected for further scrutiny using a systematic scoring algorithm. Our preliminary serum verification of the top four candidates (DSP, LAMC2, GP73, and DSG2) in 20 patients diagnosed with pancreatic cancer and 20 with benign pancreatic cysts, showed a significant (p < 0.05) elevation of LAMC2 in pancreatic cancer serum. Extensive validation of LAMC2 in healthy, benign, and PDAC sera from geographically diverse cohorts (n = 425) (Japan, Europe, and USA) demonstrated a significant increase in levels in early-stage PDAC compared with benign diseases. The sensitivity of LAMC2 was comparable to CA19.9 in all data sets, with an AUC value greater than 0.85 in discriminating healthy patients from early-stage PDAC patients. LAMC2 exhibited diagnostic complementarity with CA19.9 by showing significant (p < 0.001 in two out of three cohorts) elevation in PDAC patients with clinically low CA19.9 levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697 · cited 1×
“ROC curve construction and performance evaluation was done using the pROC package [9].”
MethodJemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“A recent study concluded that 40% of the variation in protein level is directly correlated to mRNA expression (11).”
Background
Research works printed but not linked: 31
- Singh, 2011, Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment, Pancreas, 40, 644, 10.1097/MPA.0b013e31821ff741 · DOI
- Spratlin, 2011, Looking to the future: biomarkers in the management of pancreatic adenocarcinoma, Int. J. Mol. Sci., 12, 5895, 10.3390/ijms12095895 · DOI
- Goonetilleke, 2007, Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer, Eur. J. Surg. Oncol., 33, 266, 10.1016/j.ejso.2006.10.004 · DOI · Paper page
- Singh, 2011, The clinical utility and limitations of serum carbohydrate antigen (CA19–9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma, Dig. Dis. Sci., 56, 2491, 10.1007/s10620-011-1709-8 · DOI
- Makawita, 2011, Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers, Mol. Cell. Proteomics, 10, 10.1074/mcp.M111.008599 · DOI · Paper page
- Kosanam, 2011, Mining the malignant ascites proteome for pancreatic cancer biomarkers, Proteomics, 11, 4551, 10.1002/pmic.201100264 · doi:10.1002/pmic.201100264
- DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 · DOI · Paper page
- Lianidou, 2011, Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges, Clin. Chem., 57, 1242, 10.1373/clinchem.2011.165068 · DOI · Paper page
- Haglund, 1986, Evaluation of CA 19–9 as a serum tumour marker in pancreatic cancer, Br. J. Cancer, 53, 197, 10.1038/bjc.1986.35 · DOI
- Perkins, 2003, Serum tumor markers, Am. Fam. Physician, 68, 1075
- Lu, 2004, Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue, Proteomics, 4, 3975, 10.1002/pmic.200300863 · DOI
- Cui, 2009, Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma, Pancreatology, 9, 89, 10.1159/000178879 · doi:10.1159/000178879
- Turtoi, 2011, Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma, J. Proteome Res., 10, 4302, 10.1021/pr200527z · DOI
- Kulasingam, 2010, Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer, Nat. Rev. Cancer, 10, 371, 10.1038/nrc2831 · DOI
- Planque, 2009, Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines, Mol. Cell. Proteomics, 8, 2746, 10.1074/mcp.M900134-MCP200 · DOI · Paper page
- Badea, 2008, Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia, Hepatogastroenterology, 55, 2016
- Mitsunaga, 2010, Nerve invasion distance is dependent on laminin gamma2 in tumors of pancreatic cancer, Int. J. Cancer, 127, 805, 10.1002/ijc.25104 · doi:10.1002/ijc.25104
- Dusek, 2011, Desmosomes: new perpetrators in tumour suppression, Nat. Rev. Cancer, 11, 317, 10.1038/nrc3051 · DOI · Paper page
- Ramani, 2008, Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer, BMC Cancer, 8, 373, 10.1186/1471-2407-8-373 · DOI
- Mao, 2010, Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma, Gut, 59, 1687, 10.1136/gut.2010.214916 · DOI · Paper page
- Koopmann, 2006, Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19–9, Clin. Cancer Res., 12, 442, 10.1158/1078-0432.CCR-05-0564 · DOI · Paper page
- Argani, 2001, Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE), Clin. Cancer Res., 7, 3862
- Eskelinen, 1999, Developments in serologic detection of human pancreatic adenocarcinoma, Scand. J. Gastroenterol., 34, 833, 10.1080/003655299750025273 · doi:10.1080/003655299750025273
- Hustinx, 2004, Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression, Cancer Biol. Ther., 3, 1254, 10.4161/cbt.3.12.1238 · DOI
- Slesak, 2000, Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19–9, Cancer, 89, 83, 10.1002/1097-0142(20000701)89:1<83::AID-CNCR12>3.0.CO;2-J · doi:10.1002/1097-0142(20000701)89:1<83::aid-cncr12>3.0.co;2-j
- Zhou, 1998, Identifying markers for pancreatic cancer by gene expression analysis, Cancer Epidemiol. Biomarkers Prev., 7, 109
- Moniaux, 2008, Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia, Br. J. Cancer, 98, 1540, 10.1038/sj.bjc.6604329 · DOI · Paper page
- Faca, 2008, A mouse to human search for plasma proteome changes associated with pancreatic tumor development, PLoS Med., 5, 953, 10.1371/journal.pmed.0050123 · DOI · Paper page
- Bansal, 1995, Pancreatitis is a risk factor for pancreatic cancer, Gastroenterology, 109, 247, 10.1016/0016-5085(95)90291-0 · DOI · Paper page
- Costello, 2012, New biomarkers and targets in pancreatic cancer and their application to treatment, Nature Revi., 9, 435
- Haeno, 2012, Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies, Cell, 148, 365, 10.1016/j.cell.2011.11.060 · DOI · Paper page
Cited by
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578
Barkley, D., Moncada, R., Pour, M., Liberman, D. A., Dryg, I., Werba, G., Wang, W., Baron, M., Rao, A., Xia, B., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01141-9 · Cited by 532
Liang, Y., Chen, X., Wu, Y., Li, J., Zhang, S., Wang, K., Guan, X., Yang, K., & Bai, Y. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-018-0084-9 · Cited by 260
Qiu, L., Wang, J., Chen, M., Chen, F., & Tu, W. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4634 · Cited by 88
Almeida, P. P., Cardoso, C. P., & de Freitas, L. M. (2020) · BMC Cancer · doi:10.1186/s12885-020-6533-0 · Cited by 48
Metadata
- Authors
- Kosanam, H., Prassas, I., Chrystoja, C. C., Soleas, I., Chan, A., Dimitromanolakis, A., Blasutig, I. M., Rückert, F., Gruetzmann, R., Pilarsky, C., Maekawa, M., Brand, R., & Diamandis, E. P.
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 12
- Issue
- 10
- Pages
- 2820-2832
- ISSN
- 1535-9476 (ISSN-L)
- OpenAlex
- W2117331236
- Cited by
- 118
- References
- 3
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2517 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.